^
Association details:
| Biomarker: | High NLR |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Impact of systemic inflammation markers in response to neoadjuvant pembrolizumab and chemotherapy in triple-negative breast cancer - a retrospective analysis
Published date:
12/02/2023
Excerpt:
Retrospective analysis of pts with early TNBC treated with Pemb + CTx from April 2022 to March 2023....High baseline dNLR (assessed as a continuous variable or by the median cut-off) was associated with a higher likelihood of pCR in the univariate analysis.
